Table 1.
Baseline characteristics of cohort of patients with ITP (N = 108)
| Baseline characteristic | Value |
|---|---|
| Age, y, median (range) | 53 (18‐89) |
| Female, % | 54 |
| Platelet count (×109/L) at time of complement testing, median (range) | 66 (2‐595) |
| ITP duration in years at time of complement testing, median (range) | 8.0 (0.0‐59.6) |
| Post‐splenectomy, n (%) | 17 (16) |
| Platelet autoantibody a positive, n (%) | 59 (75) |
| Anti‐GPIIb/IIIa antibodies a , n (%) | 54 (71) |
| Anti‐GPIb/IX antibodies, a n (%) | 47 (63) |
| Anti‐GPIa/IIa antibodies, a % | 31 (41) |
| On ITP treatment at time of complement testing, b n (%) | 56 (52) |
| Corticosteroids, n (%) | 18 (17) |
| Romiplostim, n (%) | 19 (18) |
| Eltrombopag, n (%) | 16 (15) |
| Rituximab, n (%) | 2 (2) |
| Fostamatinib, n (%) | 2 (2) |
| Other, n (%) | 8 (7) |
Abbreviations: GP, glycoprotein; ITP, immune thrombocytopenia.
a
Direct glycoprotein‐specific platelet autoantibody testing (PakAuto assay; Immucor, Brookfield, WI, USA) available in 76 patients at or before the time of complement testing included.
b
Fourteen patients were receiving >1 agent at the time of complement testing.